RxDoctor Payments Data

Lygia Dsa, MD

Internal Medicine · Lynbrook, NYNPI 1235201518

Payments from drug & device makers

$14,941in general payments, 2019–2025

Across 705 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$1K
  • AbbVie$1K
  • Pfizer$954
  • plus $6K from 46 others

What the payments were for

  • Food & beverage$14,941100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,941 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$122,025
Medicare patients
343
Services billed
1,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin30$46,150
OzempicSemaglutide20$42,471
FarxigaDapagliflozin Propanediol38$41,956
MounjaroTirzepatide20$41,824
EliquisApixaban35$29,473
JanuviaSitagliptin Phosphate16$24,920
XareltoRivaroxaban15$17,331
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$13,446
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$7,784
BelsomraSuvorexant11$4,578
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$4,147
SynthroidLevothyroxine Sodium40$3,103
Levothyroxine Sodium190$2,620
Rosuvastatin Calcium224$2,409
Albuterol Sulfate HfaAlbuterol Sulfate46$1,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,907$49,74051 claims
Boehringer IngelheimJardiance$1,386$46,15030 claims
Novo NordiskOzempic$2,476$42,47120 claims
Lilly USA, LLCMounjaro$1,218$41,82420 claims
MerckJanuvia, Belsomra$546$29,49827 claims
PfizerEliquis$954$29,47335 claims
Johnson & JohnsonXarelto$170$17,33115 claims
GSKTrelegy Ellipta$634$13,44616 claims
AbbVieSynthroid$1,073$3,10340 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$41$2,620190 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Lynbrook

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →